The FDA released more than 200 complete response letters (CRLs) as part of efforts to modernize and increase transparency in drug regulatory communications. While this step represents a significant move toward openness, the agency imposed certain restrictions on the disclosures. The comprehensive CRLs provide insights into reasons behind drug application rejections, potentially informing pharmaceutical development and regulatory strategy.